Oligonucleotide Therapeutics & Delivery conference Sep 22-23, LONDON, UK

Amotz Shemi, CEO, Silenseed will address ” Recent clinical progress with RNAi loaded KRAS-LODER for pancreatic tumor” on Thursday 23rd September 2021


• Introducing the RNAi loaded KRAS-LODER for targeting KRAS mutations
• Overviewing recent clinical success in phase II trials
• Presenting phase II clinical trials results including primary and secondary endpoints
• Outlining next steps of programme

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email